糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗(Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate) - 药物靶点：GR x M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor x β2-adrenergic receptor_在研适应症：哮喘，慢性支气管炎，慢性阻塞性肺疾病_专利_临床

Mechanistic 129-Xe MRI Study of Single Inhaler FF/UMEC/VI Effects in COPD Patients With Persistent, Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol (VI)-a long-acting β2-adrenergic agonist) works to treat adults with COPD. The investigators will compare the effects of this medication on adults with COPD who are at low risk of a flare-up and adults with COPD who are at high risk of a flare-up. The main questions it aims to answer are:
* Does FF/UMEC/VI improve ventilation defect percent as measured on 129-Xenon MRI in adults with moderate-severe COPD
* Evaluate the relationships between the ventilation defect percent and lung function test results
Participants will:
* Take the inhaler FF/UMEC/VI once daily for 12-weeks (optional 48-weeks)
* visit Robarts 2 times (with optional 3rd visit) for tests and imaging

开始日期2026-03-01

申办/合作机构

University of Western Ontario

NCT06905483

/ Completed临床4期IIT

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs.
The main questions it aims to answer are:
* Does BGF demonstrate a comparable effect to FUV in COPD participants?
* What medical problems do participants experience when taking BGFand FUV?

开始日期2025-04-01

申办/合作机构

Thammasat University

NCT06474039

/ Recruiting临床3期IIT

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators

开始日期2024-10-01

申办/合作机构

Mahidol University

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的临床结果

登录后查看更多信息

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的转化医学

登录后查看更多信息

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的专利（医药）

登录后查看更多信息

27

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的文献（医药）

2026-02-07·Expert Review of Pharmacoeconomics & Outcomes Research

Optimizing COPD management in Latin America: a cost-effectiveness analysis of FF/UMEC/VI in Colombia

Article

作者: Patiño, Diana Guerrero ; Buendía, Jefferson Antonio

BACKGROUND:

Chronic obstructive pulmonary disease (COPD) imposes a substantial clinical and economic burden in Colombia, particularly among older adults. Despite widespread use of dual therapy, many patients remain at high risk of exacerbations. Our objective was to evaluate the long-term cost-effectiveness of single-inhaler triple therapy (FF/UMEC/VI) versus dual therapy (FF/VI) in patients with moderate-to-severe COPD in Colombia.

RESEARCH DESIGN AND METHODS:

A Markov model was developed to simulate disease progression, healthcare costs, and quality-adjusted life years (QALYs) over a lifetime horizon, from the perspective of the Colombian healthcare system. Clinical inputs were based on randomized controlled trial data, and cost/resource use data were derived from national sources. Deterministic and probabilistic sensitivity analyses were performed.

RESULTS:

FF/UMEC/VI provided an additional 2.34 QALYs at an incremental cost of $3,013 USD versus FF/VI, resulting in an incremental cost-effectiveness ratio (ICER) of $1,287 per QALY, below the national willingness-to-pay threshold of $5,180 per QALY. Sensitivity analyses confirmed the robustness of results, with FF/UMEC/VI remaining cost-effective in >60% of simulations.

CONCLUSIONS:

FF/UMEC/VI is a cost-effective strategy for managing moderate-to-severe COPD in Colombia, offering improved clinical outcomes at an acceptable cost and supporting its adoption in treatment guidelines and reimbursement decisions.

2025-12-01·Pulmonary Therapy

Exacerbation Reduction in Patients with Asthma Following Escalation to FF/UMEC/VI from ICS/LABA: Retrospective Cohort Study

Article

作者: Moore, Alison ; Baptist, Alan P ; Laliberté, François ; Paczkowski, Rosirene ; Schell, Robert C ; Forero-Schwanhaeuser, Sergio ; Germain, Guillaume ; Klimek, Jacob ; Noorduyn, Stephen G

INTRODUCTION:

Despite fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) being available for asthma treatment in the US (United states) since 2020, real-world evidence on its clinical and economic benefits in patients with asthma is lacking. This study aimed to assess the effectiveness of FF/UMEC/VI (100/62.5/25 µg and 200/62.5/25 µg) in US patients with asthma previously on inhaled corticosteroid/long-acting β₂-agonists (ICS/LABA) using administrative claims data.

METHODS:

Retrospective, longitudinal, pre-post study utilizing data from the Komodo Health database between 09/09/2019 and 12/31/2023. Eligible adults with asthma had been treated with ICS/LABA prior to FF/UMEC/VI initiation (index date: first FF/UMEC/VI prescription). Rates of moderate-severe exacerbations, asthma-related healthcare resource utilization, oral corticosteroid (OCS) and short-acting β₂-agonist (SABA) use, and asthma-related medical costs were evaluated pre- (12 months pre-index) and post-FF/UMEC/VI initiation (12 months post-index). Statistical analyses involved rate ratios (RRs) from a Poisson regression model, odds ratios (ORs) from logistic regression models, and mean differences from linear regression models. Exploratory analyses stratified these results by pre-index ICS/LABA combination and FF/UMEC/VI index dose.

RESULTS:

In total, 17,959 patients were included. Following FF/UMEC/VI initiation, odds of having ≥ 1 exacerbation were reduced by 52% (OR [95% confidence interval (CI)] 0.48 [0.46, 0.50]; P < 0.001), rate of moderate-severe exacerbations reduced by 38% (RR [95% CI] 0.62 [0.61, 0.64]; P < 0.001) and asthma-related hospitalizations by 25% (RR [95% CI] 0.75 [0.68, 0.83]; P < 0.001). Odds of ≥ 1 OCS dispensing were reduced by 36% (OR [95% CI] 0.64 [0.62, 0.67]; P < 0.001) and ≥ 1 SABA canister use by 54% (OR [95% CI]: 0.46 [0.44, 0.48]; P < 0.001) post initiation; mean annualized asthma-related medical costs were reduced by $1115 ([95% CI] [$ -1771, $ -459]; P < 0.001). Both FF/UMEC/VI dosage groups had similar results.

CONCLUSIONS:

In patients who remain uncontrolled despite ICS/LABA treatment, escalating to FF/UMEC/VI is associated with reductions in asthma exacerbations, asthma-related hospitalizations, OCS use, SABA use, and asthma-related medical costs.

2025-07-01·Respiratory Investigation

Analysis of adherence to ICS/LAMA/LABA in patients with asthma: a retrospective observational cohort study using medical claims data

Article

作者: Yarita, Masao ; Oga, Toru ; Ito, Risako ; Mukai, Isao ; Requena, Gema ; Mita, Chifuku ; Takano, Masashi

BACKGROUND:

Real-world evidence of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) use in Japan is limited. This real-world study assessed adherence to FF/UMEC/VI once-daily single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) among patients with asthma in Japan.

METHODS:

Retrospective observational cohort study of patients with asthma initiating FF/UMEC/VI SITT or MITT, using claims data (02/18/2021-02/28/2022, JMDC database). Patients were aged ≥15 years at index (date of FF/UMEC/VI or MITT claim). Outcomes were assessed in two cohorts and weighted using inverse probability of treatment weighting: 1) 'overall cohort' included patients who received FF/UMEC/VI or MITT as initial maintenance therapy (IMT) or as non-IMT (i.e., had previously received inhaled corticosteroid-containing medication during baseline); 2) 'non-IMT cohort' was a sub-cohort of the overall cohort.

PRIMARY OUTCOME:

proportion of adherent patients (proportion of days covered ≥0.8) in the 3, 6, and 12 months after, and including, index date.

RESULTS:

The overall cohort comprised 7228 (FF/UMEC/VI) and 864 (MITT) patients. Of these, 3623 and 735 were included in the FF/UMEC/VI and MITT non-IMT cohort, respectively. At 3 months post-index, a significantly higher proportion of patients were adherent to FF/UMEC/VI (36.4 % [n = 2631]) versus MITT (31.2 % [n = 270]) in the overall cohort (rate ratio [95 % confidence interval], 1.16 [1.05-1.29], p = 0.003, weighted), and FF/UMEC/VI (36.6 % [n = 1326]) versus MITT (28.9 % [n = 213]) in the non-IMT cohort (1.26 [1.12-1.43], p < 0.001). Similar results were observed at 6, and 12 months post-index.

CONCLUSIONS:

Patients with asthma in Japan who initiated FF/UMEC/VI SITT had significantly better treatment adherence than those who initiated MITT.

172

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的新闻（医药）

2026-02-21

·有驾

中国慢阻肺治疗迎来新药突破 2026年初两大重磅新药助力精准治疗

2026年初，中国慢阻肺（COPD）治疗领域迎来两大重磅新药进展，精准生物制剂和双靶点吸入药物相继落地或申报。推动治疗从传统模式迈向更精准、更高效的双效时代。患者终于多出几条靠谱的路子，尤其是那些老三联吸入还压不住病的难缠病例。 **一、美泊利珠单抗（新可来®）：国内首个慢阻肺生物制剂已正式获批** 获批时间：2026年1月5日，国家药监局NMPA点头通过。作用原理：这是全球第一个针对IL-5的单克隆抗体，专门堵住嗜酸性粒细胞引发的炎症这条路。适合人群：血液里嗜酸性粒细胞≥150/μL的中重度患者，用了三联吸入还是反复发作、控制不好。关键效果：临床试验数据亮眼，中重度急性加重率明显下降（MATINEE研究0.80 vs 1.01；METREX研究1.40 vs 1.71）。用药方式：每个月皮下打一针，简单省事。患者依从性蹭蹭往上涨。意义：这下国内慢阻肺精准生物治疗终于开了头，填补了长期以来的空白。很多嗜酸粒细胞高的患者再也不用干熬了。**二、恩司芬群（Ensifentrine）：全球首款双靶点吸入新药，正申报上市** 申报时间：2026年1月27日。 CDE已正式受理。作用原理：PDE3/4双靶点抑制剂，一药顶两效——既能放松支气管。又能压住炎症。突出优势：不用额外加激素，特别适合对激素不耐受或者非Th2型炎症的患者。雾化吸入，用起来跟喝水一样方便，呼吸困难快速缓解。生活质量也跟着提起来。中重度急性加重风险能降28%。进展：已经在海南博鳌、澳门和大湾区先行用上，国内正式上市进入倒计时阶段。 **三、其他重要进展** 氟替美维（全再乐®）：1月22日新获批哮喘+慢阻肺双适应症，成为国内唯一单吸入三联疗法。每天只要吸一次就行。现在局面很清晰：美泊利珠单抗已经落地，直击嗜酸性粒细胞主导的那部分慢阻肺；恩司芬群申报在即。双靶点无激素吸入又给另一类患者带来新鲜选择。总的来说，2026开年这几步棋下得漂亮。慢阻肺治疗正式跨进精准化、双效化的新阶段。患者不再只有“多吸一口”这一条路，医生手里也多了精准匹配的武器。真正让控制病情、减少发作、改善生活不再是空话。

上市批准

2026-02-17

·百度百家

2026年初，中国慢阻肺（CO...@关尼讲故事的动态

2026年初，中国慢阻肺（COPD）治疗领域迎来了两大重要进展，为患者带来了更精准、更高效的治疗方案。首先是美泊利珠单抗（新可来®），这是中国首个获批用于慢阻肺的生物制剂，已于2026年1月5日获得国家药品监督管理局（NMPA）批准。该药物是全球首个靶向抑制IL-5的单克隆抗体，主要针对嗜酸性粒细胞炎症。它适用于血嗜酸性粒细胞计数≥150/μL，且使用三联吸入治疗效果仍不佳的中重度慢阻肺患者。临床数据显示，使用美泊利珠单抗后，中重度急性加重事件的发生率显著下降。每月仅需皮下注射一次，大大方便了患者的用药。这一获批标志着慢阻肺的精准生物治疗时代在中国开启，填补了国内的空白。其次是恩司芬群（Ensifentrine），这是一种全球首创的双靶点吸入新药，已于2026年1月27日提交国家药品监督管理局（CDE）审评。它的独特之处在于同时抑制PDE3和PDE4两种靶点，实现了一药双重效果：既能扩张支气管，又能抗炎。对于那些不适合使用激素或属于非Th2炎症类型的患者来说，恩司芬群是一个极佳的选择，因为它无需联合使用激素。患者通过雾化吸入即可方便用药，能有效缓解呼吸困难，提升生活质量。相较于现有治疗，它能降低中重度急性加重的风险28%。目前，该药已在海南博鳌、澳门及大湾区部分地区先行使用，国内正式上市指日可待。此外，还有其他重要进展，例如氟替美维（全再乐®）已于1月22日获批，同时可用于哮喘和慢阻肺的治疗，是目前国内唯一每日一次的吸入三联疗法药物。总结来说，美泊利珠单抗已经面市，为嗜酸性粒细胞高的慢阻肺患者提供了精准的生物治疗方案；而恩司芬群即将上市，其无激素的双靶点吸入治疗为患者带来了新的选择。

2026-02-15

·药研苑

阿斯利康布地格福治疗哮喘3期临床试验取得阳性结果

药品营销避坑”试读：药品导入期管理视频课（试听）药品生命周期管理（案例）药品立项需要注意什么（案例） 2026年2月13日，阿斯利康宣布布地格福吸入气雾剂（倍择瑞®令畅®，布地奈德/格隆溴铵/富马酸福莫特罗），用于未控制哮喘3期临床试验KALOS与LOGOS取得阳性结果，并发表于《The Lancet Respiratory Medicine》。 KALOS与LOGOS研究为重复、多中心、随机、双盲3期临床试验，共纳入4311名中高剂量吸入性糖皮质激素/长效β2-受体激动剂（ICS/LABA）不能有较控制的哮喘患者。入组患者按1:1:1:1比例随机接受布地格福吸入气雾剂（320/28.8/9.6μg）、布地格福吸入气雾剂（320μg/14.4μg/9.6μg）、布地奈德福莫特罗气雾剂（320/10μg）、布地奈德福莫特罗吸入粉雾剂（320/9μg），一天两次。治疗24周后，布地格福吸入气雾剂（320/28.8/9.6μg）组与布地奈德福莫罗汇总组晨间给药前FEV₁和FEV₁曲线下面积（AUC 0-3）分别改善76mL（95% CI 57–94; p<0.0001）和90mL（72–108; p<0.0001）。布地格福吸入气雾剂（320/28.8/9.6μg）患者严重急性发作的发生风险低于布地奈德福莫罗汇总组（RR 0.86, 95% CI 0.76–0.97; p=0.012），布地格福吸入气雾剂（320/28.8/9.6μg）、布地格福吸入气雾剂（320μg/14.4μg/9.6μg）、布地奈德福莫特罗气雾剂（320/10μg）、布地奈德福莫特罗吸入粉雾剂（320/9μg）不良事件的发生率分别为53.2%、60.0%、55.2%和58.4%（Prof Alberto Papi., 2026）。布地格福吸入气雾剂（BGF）为布地奈德（吸入糖皮质激素ICS）、格隆溴铵（长效抗胆碱能药物LAMA）、富马酸福莫特罗（长效β2受体激动剂LABA）组成的固定剂量三联吸入制剂。目前在国内获批的适应症为用于慢性阻塞性肺疾病（COPD）患者的维持治疗。推荐指数：★★★ 推荐原因：布地格福吸入气雾剂用于哮喘3期临床试验取得阳性结果，为布地格福进入哮喘领域奠定了良好基础。氟替美维吸入粉雾剂已在国内获批用于哮喘患者的维持治疗，预计布地格福吸入气雾剂会快速跟上，共同抢占市场。尽管从吸入技术上来看，粉雾剂比气雾剂更加方便，由于布地格福吸入气雾剂在国内COPD领域的市场基础更好，有助于弥补吸入技术在哮喘领域的负面影响。相关阅读：金赛药业亮丙瑞林6个月制剂治疗晚期前列腺癌研究成果发表礼来替尔泊肽国内获批单药治疗成人2型糖尿病礼来匹妥布替尼获批慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 26周减重12.1%恒瑞口服Ribupatide 2期研究数据发布礼来米吉珠单抗国内获批中重度克罗恩病和溃疡性结肠炎拜耳达罗他胺国内获批第三项前列腺癌适应症恒瑞降尿酸药物HR091506国内上市申请获受理又一SGLT2抑制剂通关，恒翼生物贝沙格列净国内获批 2025年1-3季度口崩片市场哪个强？ 2025年1-3季度口溶膜制剂哪家强？免疫检查点抑制剂，谁将成为下一个王者？质子泵相关抑酸类药物市场即将回暖改剂型，口服液体制剂“金矿”还是“陷阱” 相关内容只作为药物研发的参信息。不构成任何与用药咨询有关的建议。如需发稿，您可通过在药研苑公众号下以发送信息的方式将官网或官方公众号的稿件链接和标题发送给我们。我们将择优确定是否发布。

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	R03AL08	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	加拿大	GlaxoSmithKline, Inc.	2018-05-30
慢性支气管炎	加拿大	GlaxoSmithKline, Inc.	2018-04-04
慢性阻塞性肺疾病	美国	GlaxoSmithKline Intellectual Property Development Ltd.	2017-09-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性哮喘	临床3期	美国	GSK Plc	2023-04-25
急性哮喘	临床3期	阿根廷	GSK Plc	2023-04-25
急性哮喘	临床3期	澳大利亚	GSK Plc	2023-04-25
急性哮喘	临床3期	智利	GSK Plc	2023-04-25
急性哮喘	临床3期	新西兰	GSK Plc	2023-04-25
急性哮喘	临床3期	韩国	GSK Plc	2023-04-25
心血管疾病	临床3期	美国	Glaxo Group Ltd.	2012-01-25
心血管疾病	临床3期	美国	葛兰素史克（中国）投资有限公司	2012-01-25
心血管疾病	临床3期	日本	葛兰素史克（中国）投资有限公司	2012-01-25
心血管疾病	临床3期	日本	Glaxo Group Ltd.	2012-01-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04937387 (CTgov)	临床3期	哮喘	359	Fluticasone Furoate [FF]+Vilanterol [VI] (Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug)	構遞鑰憲積膚顧糧簾壓(選選夢鏇壓鹹範艱鏇鬱) = 衊憲襯顧憲壓積鏇廠觸壓觸衊築廠齋觸餘齋遞 (襯製醖網淵鑰鬱遞廠壓, 0.0321) 更多	-	2025-08-11
				Fluticasone Furoate [FF]+Vilanterol [VI]+Umeclidinium [UMEC] (Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug)	構遞鑰憲積膚顧糧簾壓(選選夢鏇壓鹹範艱鏇鬱) = 齋衊觸鬱淵壓獵鏇積鏇壓觸衊築廠齋觸餘齋遞 (襯製醖網淵鑰鬱遞廠壓, 0.0316) 更多
ATS2025	临床3期	慢性阻塞性肺疾病 St George's Respiratory Questionnaire (SGRQ)-C questions 1 (cough)	-	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	繭餘鹹廠膚願廠鑰憲構(顧鑰鹹顧願淵壓憲廠襯) = 餘鏇廠築憲願製餘憲醖餘顧選鑰鑰膚淵窪夢遞 (築積顧艱築衊鏇淵鬱衊 )	积极	2025-05-16
				Budesonide/Formoterol (BUD/FOR)	繭餘鹹廠膚願廠鑰憲構(顧鑰鹹顧願淵壓憲廠襯) = 衊積齋艱積選糧襯糧衊餘顧選鑰鑰膚淵窪夢遞 (築積顧艱築衊鏇淵鬱衊 )
NCT04923347 (CTgov)	临床4期	慢性阻塞性肺疾病	229	fluticasone furoate+vilanterol+umeclidinium	襯簾膚糧淵鏇遞襯製壓 = 糧窪鏇鏇鬱鹹築襯鬱艱築醖願淵構襯鏇觸獵範 (觸窪築膚窪範廠構衊鹹, 憲廠艱蓋糧醖窪艱積觸 ~ 蓋積鹹憲鹽製遞糧艱簾) 更多	-	2025-03-24
NCT05535972 (CTgov)	临床4期	慢性阻塞性肺疾病	463	fluticasone furoate+vilanterol+Trelegy+umeclidinium	夢膚築衊遞衊鬱餘築獵(獵齋襯淵齋夢膚範願蓋) = 製顧醖鏇衊膚糧製觸廠齋壓鏇鬱窪艱膚窪範鑰 (廠餘簾願襯糧糧衊網齋, 5.49) 更多	-	2024-11-04
NCT02924688 (CAPTAIN, ERS2024)	临床3期	-	814	FF/UMEC/VI 200/62.5/25μg	鬱膚餘窪憲糧鬱襯夢選(壓糧觸範鏇憲獵膚鹽願) = 淵艱網齋餘糧餘願醖窪衊廠壓願醖壓膚願積膚 (積蓋艱鏇繭觸構鏇鹽鬱 )	积极	2024-09-07
ATS2024	N/A	慢性阻塞性肺疾病 \| 哮喘	-	FF/UMEC/VI-100	顧齋壓獵醖獵願簾獵鹽(鏇衊構遞鑰鑰鹽網醖構) = 觸範選淵憲衊襯遞蓋構製糧壓選窪願艱鬱築鏇 (夢顧淵鏇餘鬱壓鏇鬱憲 ) 更多	-	2024-05-19
				FF/UMEC/VI-200	顧齋壓獵醖獵願簾獵鹽(鏇衊構遞鑰鑰鹽網醖構) = 壓夢淵製夢製鹽憲獵夢製糧壓選窪願艱鬱築鏇 (夢顧淵鏇餘鬱壓鏇鬱憲 ) 更多
NCT02924688 (CAPTAIN, ATS2024)	临床3期	哮喘维持	-	FF/UMEC/VI 100/62.5/25mcg	簾遞襯襯範築鹽鹹餘鏇(範鹹憲憲窪簾選築鏇窪) = 壓齋獵選窪遞願鬱蓋壓夢鏇膚膚膚糧壓窪憲糧 (壓夢衊網鹹膚獵簾衊糧 )	-	2024-05-19
				FF/UMEC/VI 200/62.5/25mcg	簾遞襯襯範築鹽鹹餘鏇(範鹹憲憲窪簾選築鏇窪) = 繭鑰餘憲積鏇鹽醖壓網夢鏇膚膚膚糧壓窪憲糧 (壓夢衊網鹹膚獵簾衊糧 )
ATS2024	N/A	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol	願憲膚醖廠夢網積襯構(顧遞鬱蓋廠製顧鹹壓製) = 膚鑰襯繭願範獵簾積顧選願範簾鏇糧觸範夢鑰 (鑰餘網築鬱顧獵構鑰積 )	-	2024-05-19
				Budesonide/Formoterol	願憲膚醖廠夢網積襯構(顧遞鬱蓋廠製顧鹹壓製) = 淵築鹽鹹壓觸築構築蓋選願範簾鏇糧觸範夢鑰 (鑰餘網築鬱顧獵構鑰積 )
ATS2024	N/A	慢性阻塞性肺疾病	-	Prompt initiation of FF/UMEC/VI	選艱廠獵鏇顧鑰顧膚窪(窪醖願築積鏇網窪範鑰) = 積觸淵願構築製襯壓憲蓋獵齋淵廠鬱鏇鹹蓋鏇 (壓夢鹹齋築鹹蓋夢壓醖 ) 更多	积极	2024-05-19
				Delayed initiation of FF/UMEC/VI	選艱廠獵鏇顧鑰顧膚窪(窪醖願築積鏇網窪範鑰) = 蓋蓋齋鹽願壓膚壓膚淵蓋獵齋淵廠鬱鏇鹹蓋鏇 (壓夢鹹齋築鹹蓋夢壓醖 ) 更多
NCT04651777 (ETHA, CTgov)	临床3期	哮喘	31	FF/UMEC/VI	艱遞鬱衊顧鹽蓋衊齋鹽(壓糧遞膚顧鹹廠艱蓋襯) = 獵鹽窪顧顧醖遞廠膚顧鏇廠蓋蓋願積衊獵築積 (廠製構構鏇醖淵艱範觸, 12) 更多	-	2024-03-29